Patents not ‘limiting factor’ for vaccine production: BioNTech
Four-month rifapentine regimen with moxifloxacin noninferior for TB
6 May 2021Mayo Clinic Minute: Lifestyle changes to manage menopause symptoms
6 May 2021Patents not ‘limiting factor’ for vaccine production: BioNTech
German firm BioNTech said Thursday that patent protection for COVID-19 vaccines is not holding back production or supply of the jabs that it developed with Pfizer.
